Related Experiment Video
Updated: Jul 25, 2026

Microsurgical Clip Obliteration of Middle Cerebral Aneurysm Using Intraoperative Flow Assessment
Published on: September 25, 2009
Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: An Analysis of 35 Consecutive Patients
Salvatore Palumbo1, Kimon Bekelis2, Symeone Missios3
1Neurosurgery, Good Samaritan University Hospital, West Islip, USA.
Introduction:
There is sufficient scientific literature that demonstrates favorable outcomes using the minimally invasive technique of middle meningeal artery embolization (MMAE) for the treatment of chronic subdural hematomas (cSDH). The authors evaluate the outcomes of 35 consecutive patients treated with MMAE, both with and without adjuvant surgical drainage (ASD), in an attempt to identify variables that may affect the outcome of patients treated with MMAE for cSDH.
Methods:
A multivariate retrospective analysis was performed on patients who received MMAE for cSDH, including age, size of cSDH, ASD, presence of unilateral or bilateral collections, and use of anticoagulants.
Results:
Twenty patients underwent MMAE with planned ASD, while 15 patients had MMAE only; these groups had an average cSDH size reduction (measured at its greatest width) of 74% and 69% of cSDH, respectively. Of the 15 patients who were initially treated only with MMAE, three (20%) required a rescue craniotomy. Twenty patients (57%) who had initially presented while receiving oral anticoagulants had an average of 71% size reduction with ASD compared to 74% reduction in those without ASD. Patients not using anticoagulants had an 84% and 78% average reduction in size, respectively. Twelve patients presented with bilateral cSDH; patients who received ASD had an average size reduction of 58%; those without ASD had 63%. Patients with unilateral cSDH had 85% and 83% reduction in size, respectively.
Conclusion:
Middle meningeal artery embolization, with or without ASD, can be a useful alternative or adjunct to standard surgical treatment for cSDH. Our study found that only three of 35 patients (9%) treated with this method required any further surgical intervention. No patient who received ASD had a recurrence of their cSDH. Further investigation, including prospective randomized studies, would be useful to better identify which patients can benefit and variables that impact the outcome of patients undergoing MMAE.
Insights
Middle meningeal artery embolization (MMAE) is effective for chronic subdural hematomas (cSDH), with or without adjuvant surgical drainage (ASD). Only 9% of patients required further intervention, and no ASD patients experienced recurrence.
Area of Science:
- Neurosurgery
- Interventional Radiology
- Vascular Surgery
Background:
- Chronic subdural hematomas (cSDH) can be treated with minimally invasive middle meningeal artery embolization (MMAE).
- Favorable outcomes are documented in scientific literature for MMAE in cSDH treatment.
- This study evaluates MMAE outcomes, with and without adjuvant surgical drainage (ASD), to identify outcome-influencing variables.
Purpose of the Study:
- To evaluate the outcomes of patients treated with MMAE for cSDH.
- To compare MMAE with and without ASD.
- To identify variables affecting MMAE outcomes in cSDH patients.
Main Methods:
- Multivariate retrospective analysis of 35 consecutive cSDH patients treated with MMAE.
- Variables analyzed included age, cSDH size, ASD use, collection laterality, and anticoagulant use.
- Comparison of outcomes between MMAE-only and MMAE with ASD groups.
Main Results:
- MMAE with ASD (n=20) and MMAE only (n=15) showed average cSDH size reductions of 74% and 69%, respectively.
- Only 3 of 35 patients (9%) required rescue craniotomy; none of the 20 patients receiving ASD had recurrence.
- Anticoagulant use was associated with slightly lower size reduction (71-74%) compared to non-anticoagulant users (78-84%).
Conclusions:
- MMAE, with or without ASD, is a viable alternative or adjunct to standard surgical treatment for cSDH.
- The low rate of subsequent surgical intervention (9%) highlights MMAE's efficacy.
- Further prospective studies are needed to optimize patient selection and understand outcome variables for MMAE in cSDH.
More Related Videos
Related Concept Videos
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology

